4 Healthcare Stock Stories for Weekend Investment Wellness

Johnson & Johnson (NYSE:JNJ): Current price $81.82

The United States Court of Appeals for the Federal Circuit has reversed a Texas jury, ruling that the company’s subsidiary Cordis Corp. did not infringe on a patent owned by a radiologist in making its Cypher stents. The decision effectively undoes a ruling by a lower court that ordered Cordis to pay $482 million. The appeals court ruled that Cordis had not infringed.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

JNJ

Pfizer (NYSE:PFE) Current price $29.20

The firm recently reported that it has won conditional marketing authorization from the European Commission for its oncology product, Bosulif (bosutinib). Bosulif gained conditional EU approval for the treatment of adults suffering from chronic, accelerated, and blast phase Philadelphia chromosome positive chronic myelogenous leukemia that has been prior to this time treated with one or more tyrosine kinase inhibitors and for whom treatments like Novartis’ Gleevec (imatinib) and Tasigna (nilotinib) and Bristol-Myers Squibb Company’s Sprycel (dasatinib) are not considered suitable.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

PFE

Acura Pharmaceuticals (NASDAQ:ACUR): Current price $2.20

The specialty pharmaceutical company has announced that it has been issued Patent No. 8,409,616 by the United States Patent and Trademark Office, which covers, among other inventions, Acura’s Aversion polymer matrix tech, when utilized with any water soluble drug of abuse. The opioid products that Acura is developing are covered by this patent.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ACUR

Furiex Pharmaceuticals (NASDAQ:FURX): Current price $34.53

The drug development collaboration firm, reported Thursday that it will receive a $5 million milestone payment from the Menarini Group for the intro of Priligy in France. Presently, Priligy is marketed for on-demand treatment of sexual dysfunction in 16 countries in Europe, Asia and Latin America, and is okayed for that indication in 56 countries worldwide. In May 2012, Furiex made a license agreement with Menarini to commercialize Priligy in Europe, the majority of Asia, Africa, Latin America and the Middle East.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

FURX

Don’t Miss: 3 Simple Steps to Improve Your Retirement Nest Egg.